Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1012MR)

This product GTTS-WQ1012MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1012MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2022MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGT-181
GTTS-WQ4470MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ9531MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ7176MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ6300MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ5521MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ12366MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ4564MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-936564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW